471 results about "Intraperitoneal route" patented technology

The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4. The invention also provides a method of protecting a mammal from CPE toxicity involving administering a protective agent that binds to claudin-3 and/or claudin-4 and inhibits CPE binding to claudin-3 and/or claudin-4.

A prosthesis for the treatment of hernias and/or laparoceles via an intraperitoneal route, having a mesh of filaments of non-resorbable and biocompatible polymer material having interstices permitting tissue growth and a sheet of polymer material having barrier properties and low adhesion to sensitive organs and tissues. The sheet is superimposed upon and joined to the mesh so as to form a stratified structure. In particular, the sheet is joined to mesh through a plurality of filaments located alongside each other at a spacing of not more than 5 mm. Each filament has a plurality of attachment sites to the mesh which are not more than 15 mm apart, and each length of filament between two successive attachment sites projects from the surface of the mesh facing sheet and is fused to the sheet.

The invention relates to a preparation method of a 2-type diabetic nephropathy model. The method comprises the following steps of: selecting a male SHR (spontaneously hypertensive rat) rat with an age of 6 weeks, wherein the blood pressure of the male SHR rat at birth is normal, and at the time of 4 weeks, the blood pressure begins to rise; after adaptively feeding the SHR rat selected in the step (1) for one week, feeding a high sugar and high fat feed for 2 weeks; detecting the weight, the blood fat, the blood sugar and the insulin concentration and calculating an insulin resistance index evaluated by a steady-state model, wherein the insulin resistance index is not smaller than 3.8, and the high fat and high sugar feed comprises the following components in percentage by weight: 10.0 percent of lard, 20.0 percent of cane sugar, 2.5 percent of cholesterol, 2.0 percent of cholate and 66.5 percent of conventional feed; after fasting the insulin resistant SHR rat for 12 hours, carrying out a small-dose one-time STZ (streptozocin) (35mg/kg) intraperitoneal injection on the SHR rat, wherein the small dose is 35mg/kg; after 72 hours, measuring the random blood sugar; and judging the 2-type diabetic nephropathy model to be successfully prepared if the plasma glucose is not smaller than 16.7mmol/L.

Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.

The invention relates to a Bacillus velezensis, and a micro-ecological preparation and preparation method thereof. The Bacillus velezensis is preserved in China Center for Type Culture Collection, hasa strain preservation number of CCTCC NO: M 2019218, and is classified and named as Bacillus velezensis BvL03, and the Latin academic name is Bacillus velezensis BvL03. The micro-ecological preparation suitable for aquiculture prepared by the strain has broad-spectrum effect of inhibiting fish pathogenic bacteria through drug-delivery routes such as feed addition, water body sprinkling or intraperitoneal injection, and the protection rate reaches 85 percent. After acting on fish bodies, the preparation can effectively prevent fish pathogenic bacteria such as aeromonas hydrophila from infecting freshwater fishes such as grass carps and crucian carps, and particularly has the best protection effect on grass carps.

The invention discloses a method for inducing a rat liver cancer model by injecting diethyl nitrosamine DEN in coordination with microcystin MC-LR into a rat body through intraperitoneal injection. Indexes such as liver weight to body weight ratio, liver appearance, liver histopathological slicing and GST-Pi (Glutathione S-transferase) protein expression level clearly show liver cell injury phase, liver cell hyperplasia-hepatocirrhosis phase and liver cell carcinomatous change process in a rat liver cancer occurring process, and find that the liver cancer model induced by the DEN in coordination with the microcystin MC-LR has a more obvious effect at the same time than that induced by DEN independently; the tumor formation time is shorter; and the model is an ideal model for researching occurrence of the liver cancer of a human body. The model has the characteristic of clearly showing each stage for occurrence of the liver cancer and contributing to research of a liver cancer occurrence process mechanism, detection of precancerous lesion and development of treatment medicaments.

The invention relates to pelteobagrus fulvdraco sperm ultralow temperature freezing storage and recovery method. Parent pelteobagrus fulvdraco which is in good shape and good growth, has no disease and is sexually mature is selected, 30Mug/kg LHRH-A2 intraperitoneal injection is carried out to induce sperm increasing, after 36 hours, dissection is carried out to obtain spermary, and the spermary is cut into pieces in a clean mortar cooled in a refrigerator at 4 DEG C in advance, the pieces are diluted by Ringers solution in the proportion of 1:6, balancing is carried out for 30min at 4 DEG C, 10% methyl alcohol is added, and mixing to be uniform is carried out, packaging is carried out, balancing is carried out for 10min 6cm above liquid nitrogen surface, and balancing is carried out for 5min on the liquid nitrogen surface, and then the product is thrown into liquid nitrogen to be stored. Water bath ate 37 DEG C is carried out, activation solution SM is used for activation, pelteobagrus fulvdraco roe is extruded into a container, frozen sperm is added in drops in the sperm roe quantity ratio of 105:1, stirring to be uniform is carried out, then appropriate activation solution SM is added in drops, and stirring to be uniform is carried out, so that fertilization of roe is carried out. The sperm stored by the invention has high quality, has insemination capability and has important theoretical significance and application value on seed quality saving, inheritance breeding, sustainable culture and disease control of pelteobagrus fulvdraco.

The invention discloses a duplication method of rat acute or persistent hyperuricemia model which comprises, (1) selecting male, female healthy rats with the specie of SD and Wistar and 150-450g of body weight, simultaneously administering purines by 100-2000 mg/kg and uric acid depressant by 5-1000mg/kg through stomach filling, hypodermic injection or abdominal cavity injection, (2) after 5-24 hours, administering the rats by the same mode and medicament dose, (3) administering the rats daily continually according to the step (1) and (2), continuing administration for one to two weeks.

The invention discloses an imaging model in small animal living bodies with echinococcus granulosus and a construction method thereof. The construction method comprises the steps of: feeding CF-1 male mice; carrying out in vitro culture and drug treatment on protoscolex; carrying out in vitro fluorescence imaging and fluorescence gradient analysis; pretreating mice with depilatory paste for experimental animals, injecting the abdominal cavity of each mouse with chloral hydrate anesthetic, implanting three groups of stained scoleces under Glisson capsules by injection, dividing the mice into three groups according to different groups of injected protoscolex; in a control group, injecting the livers of mice with protoscolex on which drug treatment is not carried out, collecting images every 12 hours after injection, carrying out fluorescence intensity analysis on the ROIs region, putting into a polyethylene cage after imaging, and carrying out in vitro fluorescence gradient detection in the positive control group. The construction method constructs a mouse model with echinococcus granulosus which can express luciferase, provides a platform for drug sensitive tests in living bodies with echinococcosis, and can monitor the growth and transfer of hydatid in the living model dynamically in a long term.

Belonging to the field of biotechnologies, the invention discloses a preparation method of a diazepam monoclonal antibody, and especially discloses application of the diazepam monoclonal antibody in the rapid detection method of ELISA. The method includes: coupling carboxylation reformed diazepam with carrier protein by an EDC technique, immunizing 5-6-week-old Balb/c mice by intraperitoneal injection, taking spleen from the mouse with positive binding activity and competitive activity to conduct cell fusion and carrying out screening to prepare the monoclonal antibody, and optimizing reaction conditions, determining the concentration of optimal coating antigen DZP-OVA at 1.25 microgram/mL and the optimal antibody dilution factor at 1:16000, thus establishing the ELISA method for the rapid detection of diazepam. The lowest detection limit IC10 of the method is 0.0011 microgram/mL. The invention provides the basic reagent antibody for immunoassay of diazepam and the detection method.

The invention relates to a tanshinone IIA phosphate phenolic ester derivative and a preparation process thereof. The derivative and the preparation process thereof have the advantages that firstly, the new derivative of tanshinone IIA is provided, and the new substance can serve as a drug for treating cerebrovascular diseases; secondly, the tanshinone IIA phosphate phenolic ester derivative is good in water solubility and can be produced into injections conveniently. Animal experiments indicate that the tanshinone IIA phosphate phenolic ester derivative has a good pesticide effect on mouse middle cerebral artery occlusion (MCAO) through intraperitoneal injection and can be developed into the new drug for treating the cerebrovascular diseases, particularly the injection-type drug for treating the cerebrovascular diseases. The derivative serves as an important prodrug and has the high application value clinically.

The invention provides a method for establishment of a macaca mulatta liver fibrosis model by intraperitoneal injection. The method includes the steps of: selecting 5-9kg male macaca mulattas of 2-3 years old as the model animals, performing feeding with high-fat feed during modeling, supplying an alcohol water solution with a volume concentration of 9%-11% for drinking, and injecting CCl4 injection to each macaca mulatta during modeling twice a week by intraperitoneal injection continuously for 20-30 weeks, and controlling the injecting amount at 0.8-1.5mL/kg each time, thus achieving successful modeling. The animal model establishment method provided by the invention is simple, safe and reliable, has the characteristics of short modeling time, high success rate, good repeatability, goodanimal tolerance and low death rate, and can be used for studying the pathogenesis, pathogenic factors and treatment means of chronic liver diseases.

The invention provides a B-group epidemic neisseria meningitidis recombinant protein vaccine and a preparing method thereof, and belongs to the field of biological products. The vaccine contains three mutant recombinant proteins of a human H factor binding protein. The invention further provides a preparing method of the B-group epidemic neisseria meningitidis recombinant protein vaccine. The method includes the steps of human H factor binding protein V1, V2 and V3 recombinant expression carrier construction, expression strain screening and identification, fermental cultivation, recombinant protein antigen inducible expression and recombinant protein antigen purification and protein detection; and according to the concentrations of the three antigen components, quantified mixing is carried out, and the B-group epidemic neisseria meningitidis recombinant protein vaccine is prepared in cooperation with an aluminum adjuvant. By means of the B-group epidemic neisseria meningitidis recombinant protein vaccine, intraperitoneal injection is carried out on an immune mice, the mice body can be stimulated to generate a B-group epidemic neisseria resisting peculiar antibody, and the alexin mediated serum sterilization antibody can rise by more than 8 times.

The invention relates to a chloramphenicol-resistant monoclonal antibody, which is mainly used for detecting chloramphenicol residue in livestock products and milk products. The chloramphenicol-resistant monoclonal antibody is secreted from a hybridoma cell line 7C10; and the preparation method comprises the following steps of: coupling EDC-activated chloramphenicol and carrier protein to obtain immunogen and coating antigen; performing intraperitoneal injection of mouse immunogen and enhancing the immunity; screening out a mouse who is subjected to immunity enhancement and has high serum titer; fusing spleen cells and SP2/0 myeloma cells; performing sub-clone to obtain the monoclonal antibody hybridoma cell line 7C10 capable of stably secreting the chloramphenicol; performing intraperitoneal injection on the mouse with the hybridoma cell line 7C10; collecting ascitic fluid; and performing liquid-phase chromatographic purification to obtain the chloramphenicol-resistant monoclonal antibody 7C10'. The chloramphenicol-resistant monoclonal antibody has the advantages of high specificity, high flexibility and affinity, large-scale production and effect of quickly and sensitively detecting the chloramphenicol residue in foods such as milk, meats, aquatic products and the like.

The invention relates to the technical field of establishment of animal experiment models and in particular relates to a method for establishing a fish inflammatory bowel disease model and the established model thereof. The method comprises the following steps: injecting aeromonas hydrophila with the collection number of CCTCC NO.M2013089 into a soaked anaesthetic healthy fish through anus perfusion, breeding and selecting fish with the symptom of the inflammatory bowel disease as the fish inflammatory bowel disease model. According to the method, the aeromonas hydrophila is directly filled in the intestinal tract of the fish, and the process that the pathogenic bacteria enter blood through intramuscular injection or intraperitoneal injection and act on the intestinal tract through blood circulation is avoided, so that the pathogenic bacteria directly act on the intestinal tract, and the pertinence is improved; furthermore, the established model has high stability and repeatability, and because the aeromonas hydrophila is wide in infection spectrum, the established method can be widely applied to multiple fishes.

The invention relates to novel use of methylene blue (MB) in prevention of acute cerebral ischemia. MB can remarkably reduce cerebral ischemia infarction caused by permanent middle cerebral artery occlusion (middle cerebral artery occlusion MCAO) and alleviate damage of neurological function. The inventors of the invention permanently occlude middle cerebral artery of a mouse by adopting a suture method and after intraperitoneal injection of MB at the moment and at different time points after cerebral ischemia, changes on degree and ethology of permanent cerebral ischemia infarction of the mouse are observed. Researches discover that MB can remarkably reduce infarct volume caused by cerebral ischemia and improve the active ability of the mouse after cerebral ischemia. Through the method provided by the invention, moderate doses of MB are delivered for many times after cerebral ischemia can remarkably alleviate damage degree after permanent cerebral ischemia of the mouse so as to improve the active ability of the mouse after cerebral ischemia. The use of MB is expected to provide a rescue therapeutic measure to cerebral apoplexy and alleviate permanent neurological function deficit after golden treatment period.

The invention discloses a building method of an ulcerative colitis transformation animal model. By using the method, an inflammatory transformation model combining with clostridium difficile in a DSSacute colitis model is built; and different bacterium feeding modes, including three measures of intraperitoneal injection, gastric perfusion and enema are used. The model has the advantages that theproportion of mouse mesenteric lymphocytes Th17 can be obviously increased by the model; the secretion of IL-17 is increased; the result is more similar to the pathological features of clinic patientswith ulcerative colitis; and the clostridium difficile feeding effect on the mice through gastric perfusion is best.

The invention discloses an application of an antibacterial peptide C-BF in preparation of medicines for preventing and treating weanling stress of piglets. The intestinal morphology can be improved by the antibacterial peptide C-BF; the villus height can be increased; the intestinal inflammation is relieved; the growth performance of weaned pigs is improved; the diarrhea rate is lowered; and the antibacterial peptide C-BF is dosed through intraperitoneal injection.

The invention relates to designing and application of a prodrug based on a gemcitabine structure. According to the prodrug, a phosphate ester long-chain group is introduced to the position 5'-OH of a gemcitabine five-membered sugar ring, so fat-solubility and membrane permeability of the prodrug are improved. In tumors lacking nucleic acid transport protein, the fat-soluble prodrug can enter the tumors through passive diffusion and active transport to inhibit growth of the tumors. Moreover, the prodrug can be orally taken, thereby obtaining a better or same curative effect of tumor growth inhibition compared with intraperitoneal injection of gemcitabine.

The invention discloses a novel EV71 virus strain of which the whole-genome length is 7405bp and the sequence is shown in SEQID NO:1. The virus strain can infect ICR, KM, BALB/c and NIH mice; the virus dosage of larger than 1*10<2>-1*10<7> TCID50 can cause the disease attack or death of 1-17 days mice; the administration route can be intraperitoneal injection, encephalocoele injection and intragastric administration; the symptoms are typical symptoms of EV71 virus infection and are divided into the following five levels according to stages of the disease: Level 0: not attacked; L1: motion incoordination and weakness of limbs; L2: hypokinesia and paralysis of fore or posterior limbs; L3: quadriplegia and dying; and L4: death. Various animal evaluation models such as an immunogenicity animal evaluation model of hand-foot-and-mouth disease vaccine and an animal evaluation model of EV71 therapeutic drug and therapeutic vaccine, can be built conveniently.

The invention provides application of an extract of radix astragali in treating cadmium-induced diabetic nephropathy. High-fat and high-sugar feeding is adopted, and by combing with intraperitoneal injection of cadmium chloride for induction, a mouse model of cadmium-induced diabetic nephropathy is constructed. Experimental studies are carried out on the pathogenesis and characteristics of cadmium-induced diabetic nephropathy and the protective effect of radix astragali from the aspects of oxidative stress level, related protein expression level and the like, and a new approach for treatment of diabetic nephropathy caused by long-term cadmium exposure and high-fat and high-sugar diet is provided.

The invention discloses a micro-nano material for preventing and/or treating myelosuppression and application thereof. A fullerene and/or metal fullerene micro-nano material can be applied to preparing medicine with at least one of the following properties of preventing and/or treating myelosuppression, removing free radicals, preventing and/or treating at least one of leukocyte reduction, platelet reduction, hemoglobin reduction and monocyte reduction caused by myelosuppression, preventing bone marrow cells and/or hematopoietic cells, improving the function of antioxidant systems of organisms and protecting liver tissue, spleen tissue and kidney tissue. The fullerene and/or metal fullerene micro-nano material can be metabolized out of organisms, is enriched in visceral organs and marrow through blood circulation after intragastric administration or intraperitoneal injection, has an excellent function of preventing myelosuppression induced by chemotherapy in bodies, can effectively reduce toxic and side effects of chemotherapy on marrow and other organs, and is still obvious in protection effect after multiple treatment courses.

The invention provides a novel GLP-1 receptor agonist, which is specifically a fusion protein formed by recombining GLP-1 receptor agonist molecules and non-antibody protein scaffold genes. The fusion protein can pass through the blood-brain barrier and enter the central nervous system Play a role. A linker molecule is also included between the GLP-1 receptor agonist molecule and the non-antibody protein scaffold. The non-antibody protein scaffold is derived from engineered human fibronectin domains with serum albumin targeting and reversible binding to human serum albumin. The novel GLP-1 receptor agonist has therapeutic effect in the field of neurodegenerative diseases. Using the method provided by the present invention to optimize exenatide, the half-life can reach 10 times that before the modification. When treating AD transgenic mice, intraperitoneal injection once a day greatly facilitates the treatment and stabilizes the blood drug concentration. The new GLP-1 receptor agonist is a prokaryotic expressed protein, which has low production cost, simple process and is more suitable for large-scale production.

The invention discloses a method for studying the mechanism of gynura divaricata influencing inflammatory factors in type-II diabetic mice, and relates to diabetes research. The method comprises the following steps: adaptively feeding 50 mice for one week, then randomly dividing into a blank control group and a model group, and feeding with normal feed and high-fat and high-sugar feed; after feeding for 4 weeks, fasting and but feeding with water for 12h overnight, weighing and marking; and injecting STZ for three days, fasting and but feeding with water for 12h overnight, firstly experimenting in advance by using a glucometer and test paper, then monitoring the tail blood glucose of the mice by using a microglucometer, and determinating, wherein the fasting blood glucose being greater than or equal to 11.1mmol/L is used as a model standard for the type-II diabetes. Type-II diabetes mouse models are replicated through coordination of a high-fat diet and intraperitoneal injection of streptozotocin, and influence on the inflammatory factors in the mice after intervention of the fresh gynura divaricate is evaluated, so that a clearer theory is provided for the treatment of the type-II diabetes by the gynura divaricate and further development of a Guangxi-characteristic Chinese herbal medicine.